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Abstract
Background: The purpose of this study was to evaluate the clinical outcomes of treatment of non-odontogenic
atypical orofacial pain using botulinum toxin-A.
Methods: This study involved seven patients (seven females, mean age 65.1 years) who had non-odontogenic
orofacial pain (neuropathic pain and atypical orofacial pain) and visited the Seoul National University Bundang
Hospital between 2015 and 2017. All medication therapies were preceded by botulinum toxin-A injections,
followed by injections in the insignificant effects of medication therapies. Five of the seven patients received
intraoral injections in the gingival vestibule or mucosa, while the remaining two received extraoral injections in the
masseter and temporal muscle areas.
Results: In five of the seven patients, pain after botulinum toxin-A injection was significantly reduced. Most of the
patients who underwent surgery for dental implantation or facial nerve reconstruction recovered after injections.
However, the pain did not disappear in two patients who reported experiencing persistent pain without any cause.
Conclusions: The use of botulinum toxin-A for the treatment of non-odontogenic neuropathic orofacial pain is
clinically useful. It is more effective to administer botulinum toxin-A in combination with other medications and
physical therapy to improve pain.
Keywords: Orofacial pain, Botulinum toxin, BTX-A
Introduction
When pain occurs in the orofacial area, it is very import-
ant to identify and diagnose its cause. Orofacial pain can
be classified into temporomandibular joint disorders,
muscle disorders, angiogenic pain, neuropathic pain, car-
diogenic pain, and atypical facial pain [1].
Tissue or nerve damage causes inflammation, and the ini-
tial inflammatory response plays a very important role in
the onset of neuropathic pain. Especially, the structures of
the trigeminal nervous system are placed in a closed space,
so that the pressure generation due to inflammation can
cause nerve damage. After the apparent trauma experience
such as dental surgery such as implant, extraction, orthog-
nathic surgery, endodontic treatment, and fracture, it
continues to suffer from burning pain. The neuropathic
pain, which is presumed to be caused by trauma, is called
painful traumatic trigeminal neuropathy and is distin-
guished from classical trigeminal neuralgia [1, 2].
Atypical facial pain may be defined as a diffuse pain
deep within the tissue, which persists without an obvious
disease or cause. Pain patterns range from dull, tingling,
to sharp or throbbing pain. The duration of the pain
may range from intermittent to persistent. This type of
pain is difficult to treat because symptoms vary and its
cause is unclear. In some cases, medications such as an-
algesics, tricyclic antidepressants, and anticonvulsants
are effective, but in many cases, medication alone is not
sufficient for treatment. Recently, treatment with botu-
linum toxin-A has been introduced [2].
Botulinum toxin is a type of neurotoxin produced by
Clostridium botulinum. It plays a role in suppressing
extracellular release of synaptic vesicles by acting on the
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nerve endings at the neuron junctions of mammals. It
also affects autonomic nerves by inhibiting the release of
acetylcholine from nerve junctions in the sweat glands
and smooth muscles. Based on this principle, botulinum
toxin-A can be applied for the treatment of neuromus-
cular diseases, especially focal tension disorders or sei-
zures. Although botulinum toxin-A is very effective for
direct muscle relaxation, it may also modulate pain
through peripheral nociceptors by inhibiting the exocyt-
osis of various neurotransmitters [3, 4]. The purpose of
this study was to analyze cases retrospectively and evalu-
ate the clinical efficacy of botulinum toxin-A in patients
with non-odontogenic orofacial pain.
Review
Among the patients who visited the dental clinic of Seoul
National University Bundang Hospital between 2015 and
2017, we studied seven patients who complained of
non-odontogenic orofacial pain. Five patients were diag-
nosed with painful traumatic trigeminal neuropathy and
two others were diagnosed with atypical orofacial pain.
This study was conducted with the approval of the Institu-
tional Review Board of the Seoul National University Bun-
dang Hospital (IRB No. B-1802-453-107). All patients
were treated with medication and physical therapy. How-
ever, these methods were either ineffective or had minimal
effect. Botulinum toxin-A (BTX-A) injection therapy was
therefore performed. The age, sex distribution, diagnosis,
and treatment methods and course of patients were sum-
marized using their medical records (Table 1).
Case 1 (Table 1, no. 2)
A 67-year-old woman visited our hospital. She complained
of severe pain in the maxillary left anterior buccal vestibule.
She also reported that her upper lip has tightened after
multiple dental implants were placed in her maxilla. Clinic-
ally and radiologically, painful traumatic trigeminal neur-
opathy was diagnosed. Two hundred milligrams of
Tegretol® (Novartis, Basel, Switzerland) was administered
twice a day for 2 weeks, and the symptoms were alleviated,
but the tightened pain on the bilateral sides of the nose per-
sisted. The dose was therefore increased for another
2 weeks. Most of the pain was alleviated, but the pain that
occurred when she moved her mouth was still present. She
therefore received the medication for two additional weeks.
The frequency and severity of the pain was reduced, but
side effects such as headache and dizziness occurred; there-
fore, 10 mg of amitriptyline (Myung-In, Seoul, Korea) was
administered once a day before bedtime and capsaicin oint-
ment (Dipental cream, Dalim BioTech, Seoul, Korea) was
applied locally at the site of the pain. A stent was made in
the maxilla and capsaicin ointment was applied to the stent
for 20 min. This stent was to be worn three times a day.
However, no improvement was observed and the pain
worsened. Thus, 100 mg of Neurontin (Pfizer Ltd., Seoul,
Korea) was administered three times daily. Electric acu-
puncture stimulation therapy (EAST, Pulse Generator
(PG)-8® (ITO Co., Tokyo, Japan)) was performed four times
at 2-week intervals, but the burning and throbbing pain on
the upper lip and tenderness of the palatal area remained.
The medication of the patient was changed to 300 mg of
Trileptal (Novartis, Basel, Switzerland) which was adminis-
tered twice daily. Although there was a slight improvement,
she still complained of persistent pain. In the upper part of
the mucosa, 250 U of Dysport (Ipsen Biopharm Ltd.,
Slough, UK) was injected. As a transient side effect, food
was spilled due to the unnatural movement of the lips at
meal time, but the pain was significantly reduced. Three
months later, the second injection of Dysport 250 U was
performed. Thereafter, the pain was alleviated and the treat-
ment was terminated.
Case 2 (Table 1, no. 4)
A 52-year-old woman was referred to an oral and max-
illofacial surgeon because of intermittent severe pain in
the left facial area after facial nerve reconstruction dur-
ing plastic surgery. During examination, the patient
complained of general stiff pain in the facial region in-
cluding the left zygoma, masseter, and temporomandibu-
lar joint area. There were also symptoms of excessive
salivation in the left cheek. The patient was diagnosed
with painful traumatic trigeminal neuropathy. Taking
Trileptal did not improve the pain; therefore, it was re-
placed with Neurontin. At the same time, 25 U of Inno-
tox (Medytox Inc., Seoul, Korea) was injected into the
left masseter and physical therapy was performed. Phys-
ical therapy was performed five times with Sellalux
(Medical United, Seoul, Korea), a low-level laser treat-
ment unit, every 1 to 2 months. Two weeks after the
first injection, the pain was significantly reduced. How-
ever, it persisted in the lower left eye and around the
zygoma. Six months later, the second injection was per-
formed with the same dose. Even though almost all the
pain was alleviated, she still complained of pain in the
stylomastoid foramen area under her left ear. Three
months later, a third injection of 25 U of Innotox was
performed and the pain was markedly reduced to a tol-
erable level.
All seven patients involved in this study were women
with ages from 52 to 71 years. Five of the seven patients
complained of pain in the oral mucosa, vestibule, teeth,
and around the lips. Two of the patients complained of
facial pain in the zygoma, masseter, and temporal
muscle. The primary drugs used were carbamazepine,
oxcarbazepine, gabapentin, pregabalin, amitriptyline, and
nortriptyline. Physical therapy with either soft laser or
EAST was performed additionally in most cases. Two of
the patients were treated with Tegretol (carbamazepine),
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six were treated with Trileptal (oxcarbazepine), six were
treated with Neurontin (gabapentin), two were treated
with Lyrica (Pregabalin), one was treated with amitriptyl-
ine, and three were treated with Sensival (nortriptyline).
Laser therapy was performed on all seven patients, while
EAST was performed on two patients. Of the seven pa-
tients, five patients complained of oral pain. They re-
ceived injections at the affected site. The remaining two
patients received injections outside the oral cavity, spe-
cifically in the masseter and temporal muscles. Three
types of BTX-A were used: Meditoxin (Medytox Inc.,
Seoul, Korea), Innotox, and Dysport (Ipsen Biopharm
Ltd., Slough, UK), and the number of injections ranged
from at least once to a maximum of three times every
3 months. In five of the patients with painful traumatic
trigeminal neuropathy, pain was significantly reduced
after BTX-A injection. The neuropathic pain in all pa-
tients who received implant surgery or facial nerve re-
construction was improved. However, in two patients
with atypical orofacial pain who complained of persistent
pain without any causative factors, the pain did not dis-
appear after the injection. These patients were referred
to the anesthesiology department for stellate ganglion
block (SGB), but this treatment was not effective either
(Table 1). After BTX-A injection, transient facial unbal-
ance, unnatural movements, and facial asymmetry oc-
curred. However, all these symptoms disappeared over
time and there were no more complaints.
Traditionally, botulinum toxin has been used to treat
strabismus and eyelid seizures. Since then, it has become
widely used for the treatment of cervical dystonia and
hyperhidrosis and for esthetic purposes [5]. Botulinum
toxin is used to reduce masseter muscle volume for fa-
cial cosmetic purposes. Additionally, it is applied for the
treatment of persistent myofascial pain and masticatory
muscle disorders [6]. In addition, when unspecified tem-
poromandibular joint pain and headache are reported,
symptoms can be improved by injecting botulinum toxin
into the masseter or temporal muscle. Botulinum toxins
have been applied in many of these areas.
When unspecified facial pain persists, various treat-
ments, ranging from conservative physical therapy and
medication to surgical treatment, can be applied. Con-
servative treatments usually include medication, physical
therapy, and splint therapy. Medication is primarily used
to treat various facial pain such as unspecified temporo-
mandibular joint disorders, neuropathic pain, atypical fa-
cial pain, and facial pain caused by rheumatoid arthritis.
The drugs used include non-steroidal anti-inflammatory
drugs (NSAIDs), analgesics, antidepressants, sedatives,
muscle relaxants, and steroids. It is most important to
diagnose the type and cause of facial pain and select the
appropriate medication [7, 8]. Physiotherapy includes
thermotherapy, cooling therapy, laser therapy, and
electrical stimulation therapy. Of these, low-level laser
therapy (LLLT) is the easiest to apply and produces no
pain or discomfort. The laser has various effects such as
improvement of vasodilation and blood circulation due
to increase of temperature, relief of pain, relaxation of
muscles, waste removal, and calming of the sensory
nerve [9–11]. If conservative treatment fails, surgical
treatment can be used, but the burden associated with
invasive surgery and the risk of complications increase.
In such cases, botulinum toxin can be a very useful ther-
apy and has already proven its effectiveness in many
studies. Freund et al. first reported treating temporo-
mandibular disorder (TMD) with botulinum toxin [12,
13]. Since it has already been proven that parafunctions
such as clenching and bruxism cause TMD, treatment
with botulinum toxin was tested, and the effect was
positive. Injecting botulinum toxin into the masticatory
muscles not only reduces parafunctions but also re-
lieves masticatory pain. The botulinum toxin inhibits
the release of acetylcholine from all parasympathetic
and cholinergic postganglionic sympathetic neurons.
Therefore, it can be applied to smooth muscles and
gland tissues. The analgesic effect of botulinum toxin is
also caused by the inhibition of acetylcholine release
and is directly associated with nociceptors. Botulinum
toxin can influence sensitizing mediators, alter afferents
derived from muscle spindles, cause physiological
changes in reflex and synergistic movements, produce
autonomic effects, and cause neuroplastic changes in
the processing of afferent somatosensory activity.
Therefore, botulinum toxin can be used effectively to
treat pain syndrome because it can relax muscles [14].
Glenn et al. conducted a study among patients treated
with botulinum toxin for complaints of orofacial pain
of unknown origin. The patients complained of various
orofacial pain such as trigeminal neuralgia, temporo-
mandibular joint disorder, chronic tensional headache,
and neuropathic pain. Their pain was significantly re-
duced after injection of botulinum toxin [15]. Thomas
et al. conducted a meta-analysis study of botulinum
toxin injections in patients with trigeminal neuralgia
and postherpetic neuralgia. They concluded that botu-
linum toxin injection can be an alternative if there are
no definitive medical solutions for pain [16].
In this study, the dose of BTX-A used varied from 20
to 200 U. These differences in injection dose are due to
differences in the conversion ratio of BTX-A. An ona-
botulinum toxin-A (ONA) to abobotulinum toxin-A
(ABO) conversion ratio is approximately 1:3 to 1:4.
And a new botulinum toxin type A (NBoNT) to onabo-
tulinum toxin-A (ONA) conversion ratio is approxi-
mately 1:1. Meditoxin and Innotox are included in new
botulinum toxin type A (NBoNT). Dysport is included
in abobotulinum toxin-A (ABO) [17, 18]. All patients
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who received BTX-A injection for non-odontogenic
orofacial pain were females. They received various med-
ications and physical therapy, but these did not improve
their symptoms. They therefore received BTX-A injec-
tions. Among these patients, traumatic neuropathic
pains resulting from postoperative complications such
as implant surgery or facial nerve reconstruction
tended to be reduced after BTX-A injection. However,
atypical facial pain with unknown cause was not re-
lieved. Although transient facial asymmetry or unbal-
ance occurred as a complication after BTX-A injection,
such complications were not a major problem because
the patient was more interested in relieving the pain
she was experiencing.
Conclusions
Combining BTX-A injections with other treatments for
traumatic trigeminal neuropathic pain that does not re-
spond to conventional medication and physical therapies
may be clinically useful. However, it is important to ex-
plain the complications of this treatment such as transi-
ent facial asymmetry to patients and to perform the
treatment only after obtaining the patient’s consent.
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